{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=6", "query": { "intervention": "Arm 2- Dose Expansion", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T12:16:13.354Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04739813", "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "obinutuzumab", "type": "BIOLOGICAL" }, { "name": "prednisone", "type": "DRUG" }, { "name": "Revlimid", "type": "DRUG" }, { "name": "Polatuzumab", "type": "BIOLOGICAL" }, { "name": "ibrutinib", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2021-07-09", "completion_date": "2031-06-18", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739813" }, { "nct_id": "NCT06120140", "title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab IV", "type": "DRUG" }, { "name": "Amivantamab SC", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" }, { "name": "Chlorhexidine", "type": "DRUG" }, { "name": "Noncomedogenic skin moisturizer", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "OTHER" }, { "name": "Tacrolimus", "type": "OTHER" }, { "name": "Zinc gluconate", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Timolol", "type": "DRUG" }, { "name": "Clobetasol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2024-02-16", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 28, "location_summary": "Chandler, Arizona • Duarte, California • Fullerton, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120140" }, { "nct_id": "NCT04303117", "title": "PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kaposi Sarcoma" ], "interventions": [ { "name": "PDS01ADC", "type": "DRUG" }, { "name": "M7824", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 80, "start_date": "2020-07-13", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04303117" }, { "nct_id": "NCT07200089", "title": "Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory" ], "interventions": [ { "name": "NT-I7", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2026-08-31", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07200089" }, { "nct_id": "NCT05394831", "title": "A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "EGFR Mutant Advanced Non-small Cell Lung Cancer" ], "interventions": [ { "name": "JIN-A02", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "J Ints Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-07-30", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05394831" }, { "nct_id": "NCT06039384", "title": "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" }, { "name": "adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-12-28", "completion_date": "2025-07-11", "has_results": true, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 5, "location_summary": "Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06039384" }, { "nct_id": "NCT05480449", "title": "Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Acute Lymphoblastic Leukemia (B-ALL)", "B Lineage Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stephan Grupp MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "0 Years to 29 Years" }, "enrollment_count": 115, "start_date": "2022-09-20", "completion_date": "2029-09-20", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05480449" }, { "nct_id": "NCT05259839", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2022-10-20", "completion_date": "2033-09", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 15, "location_summary": "Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259839" }, { "nct_id": "NCT03530397", "title": "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Selected Advanced Solid Tumors" ], "interventions": [ { "name": "MEDI5752", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel or Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 400, "start_date": "2018-04-24", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 7, "location_summary": "Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530397" }, { "nct_id": "NCT04294160", "title": "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF V600 Colorectal Cancer" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "LTT462", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "LXH254", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2020-07-22", "completion_date": "2024-09-25", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-14T12:16:13.354Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294160" } ] }